FLT3 inhibitors were shown to be safe and effective during induction, re‐induction, and post‐allogeneic stem cell transplant in patients with untreated FLT3‐mutated AML in prior systematic reviews and meta‐analyses [41, 42]. Here, FLT3 is linked to acute myeloid leukemia.